Changes of intrahepatic localization of hepatitis B core antigen in HBeAg positive patients with chronic active hepatitis B treated with interferon.
The intrahepatic distribution of hepatitis B core antigen (HBcAg) was studied in 14 HBeAg-positive patients with chronic active hepatitis B who were treated with interferon. Patients received 5 to 6 million units daily of human lymphoblastoid interferon or human diploid fibroblast interferon for 28 days. Intrahepatic HBcAg was detected by the indirect immunoperoxidase technique. Before interferon therapy, the intrahepatic HBcAg was detected almost equally in both the nucleus and cytoplasm. The expression of nuclear HBcAg decreased significantly (p less than 0.001) after interferon therapy, irrespective of the outcome for DNA polymerase and/or HBeAg/anti-HBe status. The expression of cytoplasmic HBcAg decreased significantly (p less than 0.05) only in the patients who lost DNA polymerase after treatment, whereas it increased in patients with DNA polymerase and/or HBeAg in the serum. These findings suggested that a shift of intrahepatic HBcAg from the nucleus to the cytoplasm occurred in HBeAg-positive patients with chronic active hepatitis B receiving interferon therapy.
Okuno
T
T
Department of Internal Medicine, Akashi Municipal Hospital, Japan.
Shindo
M
M
Arai
K
K
Matsumoto
M
M
Takeda
M
M
Iwai
M
M
Kashima
K
K
Sokawa
Y
Y
D000328:Adult; D002467:Cell Nucleus / Q000032:analysis; D005260:Female; D006509:Hepatitis B / Q000378:metabolism / Q000628:therapy*; D006512:Hepatitis B Core Antigens / Q000378:metabolism*; D006513:Hepatitis B e Antigens / Q000032:analysis*; D006521:Hepatitis, Chronic / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007124:Immunoenzyme Techniques; D007370:Interferon Type I / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism; D008297:Male
D006512:Hepatitis B Core Antigens; D006513:Hepatitis B e Antigens; D007370:Interferon Type I